New Product For Pfizer Specialty Takes Pulmonary Arterial Hypertension To Heart

July 2nd, 2009 by samospsipsi

Pfizer Australia announced that it has signed an agreement to acquire the local distribution rights for THELINĀ® (Sitaxentan sodium), an oral, once-daily highly selective endothelin receptor antagonist, indicated for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA/WHO Functional Class III symptoms to improve exercise ability. Efficacy has been shown in primary pulmonary hypertension and in pulmonary hypertension associated with connective tissue disease1.

More: continued here

Lap-Band Weight-Loss Surgery Can Reverse Metabolic Syndrome In Obese Teens

July 2nd, 2009 by samospsipsi

Researchers Show New Antioxidant Could Help Treat Cardiovascular Disease

July 1st, 2009 by samospsipsi

Latin America Must Cut Blood Pressure To Thrive

June 27th, 2009 by samospsipsi

Bosentan Is Cost-Effective For Patients With Moderate PAH

June 26th, 2009 by samospsipsi

Biotechnology Reports Biochemical Findings From Phase IIa Study With Hypertension Vaccine CYT006-AngQb

June 25th, 2009 by samospsipsi

Fish Protein Link To Controlling High Blood Pressure, New Study

June 24th, 2009 by samospsipsi

Expedition To Mount Everest Offers New Insights Into Chronic Disease

June 23rd, 2009 by samospsipsi

Patients Beat High Blood Pressure With IDEAL LIFE Remote Health Monitoring

June 19th, 2009 by samospsipsi

Researchers Compare Different Systems Of Measuring Treatment Intensity In Hypertension Care

June 19th, 2009 by samospsipsi

Archives






Categories



Blogroll

Meta